Skip to main content
NASDAQ:VRNA

Verona Pharma Competitors

$5.90
+0.10 (+1.72 %)
(As of 05/14/2021 11:07 AM ET)
Add
Compare
Today's Range
$5.90
$5.90
50-Day Range
$5.83
$9.09
52-Week Range
$3.83
$15.71
Volume10 shs
Average Volume108,916 shs
Market Capitalization$341.82 million
P/E RatioN/A
Dividend YieldN/A
Beta0.4

Competitors

Verona Pharma (NASDAQ:VRNA) Vs. CMPS, PMVP, INVA, ENDP, ARQT, and IMGN

Should you be buying VRNA stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Verona Pharma, including COMPASS Pathways (CMPS), PMV Pharmaceuticals (PMVP), Innoviva (INVA), Endo International (ENDP), Arcutis Biotherapeutics (ARQT), and ImmunoGen (IMGN).

Verona Pharma (NASDAQ:VRNA) and COMPASS Pathways (NASDAQ:CMPS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, profitability, institutional ownership, risk and valuation.

Profitability

This table compares Verona Pharma and COMPASS Pathways' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Verona PharmaN/A-115.93%-73.68%
COMPASS PathwaysN/AN/AN/A

Valuation & Earnings

This table compares Verona Pharma and COMPASS Pathways' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Verona PharmaN/AN/A$-40,780,000.00($3.10)-1.90
COMPASS PathwaysN/AN/A$-19,610,000.00N/AN/A

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Verona Pharma and COMPASS Pathways, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Verona Pharma00303.00
COMPASS Pathways00703.00

Verona Pharma presently has a consensus target price of $19.3333, indicating a potential upside of 227.68%. COMPASS Pathways has a consensus target price of $70.80, indicating a potential upside of 108.54%. Given Verona Pharma's higher possible upside, equities research analysts clearly believe Verona Pharma is more favorable than COMPASS Pathways.

Insider and Institutional Ownership

54.5% of Verona Pharma shares are owned by institutional investors. Comparatively, 15.8% of COMPASS Pathways shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

COMPASS Pathways beats Verona Pharma on 4 of the 6 factors compared between the two stocks.

PMV Pharmaceuticals (NASDAQ:PMVP) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, valuation, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares PMV Pharmaceuticals and Verona Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PMV PharmaceuticalsN/AN/AN/AN/AN/A
Verona PharmaN/AN/A$-40,780,000.00($3.10)-1.90

Analyst Recommendations

This is a summary of current ratings and price targets for PMV Pharmaceuticals and Verona Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
PMV Pharmaceuticals01302.75
Verona Pharma00303.00

PMV Pharmaceuticals presently has a consensus price target of $38.00, indicating a potential upside of 19.05%. Verona Pharma has a consensus price target of $19.3333, indicating a potential upside of 227.68%. Given Verona Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Verona Pharma is more favorable than PMV Pharmaceuticals.

Institutional & Insider Ownership

69.7% of PMV Pharmaceuticals shares are owned by institutional investors. Comparatively, 54.5% of Verona Pharma shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares PMV Pharmaceuticals and Verona Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PMV PharmaceuticalsN/AN/AN/A
Verona PharmaN/A-115.93%-73.68%

Summary

PMV Pharmaceuticals beats Verona Pharma on 3 of the 5 factors compared between the two stocks.

Innoviva (NASDAQ:INVA) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Earnings & Valuation

This table compares Innoviva and Verona Pharma's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Innoviva$261.02 million4.96$157.29 million$1.438.94
Verona PharmaN/AN/A$-40,780,000.00($3.10)-1.90

Innoviva has higher revenue and earnings than Verona Pharma. Verona Pharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

71.5% of Innoviva shares are held by institutional investors. Comparatively, 54.5% of Verona Pharma shares are held by institutional investors. 0.3% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Innoviva and Verona Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Innoviva67.16%53.99%28.92%
Verona PharmaN/A-115.93%-73.68%

Analyst Ratings

This is a summary of current ratings and target prices for Innoviva and Verona Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Innoviva10001.00
Verona Pharma00303.00

Innoviva presently has a consensus target price of $10.00, suggesting a potential downside of 21.88%. Verona Pharma has a consensus target price of $19.3333, suggesting a potential upside of 227.68%. Given Verona Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Verona Pharma is more favorable than Innoviva.

Volatility and Risk

Innoviva has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.

Summary

Innoviva beats Verona Pharma on 10 of the 13 factors compared between the two stocks.

Endo International (NASDAQ:ENDP) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership.

Volatility and Risk

Endo International has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500.

Profitability

This table compares Endo International and Verona Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Endo International-5.30%-85.80%7.19%
Verona PharmaN/A-115.93%-73.68%

Insider and Institutional Ownership

80.0% of Endo International shares are owned by institutional investors. Comparatively, 54.5% of Verona Pharma shares are owned by institutional investors. 1.5% of Endo International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Endo International and Verona Pharma's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Endo International$2.91 billion0.44$-422,640,000.00$2.382.33
Verona PharmaN/AN/A$-40,780,000.00($3.10)-1.90

Verona Pharma has lower revenue, but higher earnings than Endo International. Verona Pharma is trading at a lower price-to-earnings ratio than Endo International, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Endo International and Verona Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Endo International23202.00
Verona Pharma00303.00

Endo International presently has a consensus target price of $7.6667, suggesting a potential upside of 38.39%. Verona Pharma has a consensus target price of $19.3333, suggesting a potential upside of 227.68%. Given Verona Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Verona Pharma is more favorable than Endo International.

Summary

Endo International beats Verona Pharma on 7 of the 13 factors compared between the two stocks.

Arcutis Biotherapeutics (NASDAQ:ARQT) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation.

Profitability

This table compares Arcutis Biotherapeutics and Verona Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Arcutis BiotherapeuticsN/A-81.74%-57.72%
Verona PharmaN/A-115.93%-73.68%

Institutional & Insider Ownership

79.6% of Arcutis Biotherapeutics shares are held by institutional investors. Comparatively, 54.5% of Verona Pharma shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Arcutis Biotherapeutics and Verona Pharma's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcutis BiotherapeuticsN/AN/A$-42,000,000.00($22.78)-1.12
Verona PharmaN/AN/A$-40,780,000.00($3.10)-1.90

Verona Pharma is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Arcutis Biotherapeutics and Verona Pharma, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Arcutis Biotherapeutics00403.00
Verona Pharma00303.00

Arcutis Biotherapeutics presently has a consensus target price of $54.6667, indicating a potential upside of 115.39%. Verona Pharma has a consensus target price of $19.3333, indicating a potential upside of 227.68%. Given Verona Pharma's higher probable upside, analysts clearly believe Verona Pharma is more favorable than Arcutis Biotherapeutics.

ImmunoGen (NASDAQ:IMGN) and Verona Pharma (NASDAQ:VRNA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for ImmunoGen and Verona Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
ImmunoGen03402.57
Verona Pharma00303.00

ImmunoGen currently has a consensus price target of $10.10, indicating a potential upside of 49.63%. Verona Pharma has a consensus price target of $19.3333, indicating a potential upside of 227.68%. Given Verona Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Verona Pharma is more favorable than ImmunoGen.

Profitability

This table compares ImmunoGen and Verona Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
ImmunoGen-77.65%N/A-26.98%
Verona PharmaN/A-115.93%-73.68%

Institutional and Insider Ownership

73.0% of ImmunoGen shares are held by institutional investors. Comparatively, 54.5% of Verona Pharma shares are held by institutional investors. 3.8% of ImmunoGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

ImmunoGen has a beta of 1.65, indicating that its share price is 65% more volatile than the S&P 500. Comparatively, Verona Pharma has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

Valuation & Earnings

This table compares ImmunoGen and Verona Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunoGen$82.27 million16.26$-104,130,000.00($0.70)-9.56
Verona PharmaN/AN/A$-40,780,000.00($3.10)-1.90

Verona Pharma has lower revenue, but higher earnings than ImmunoGen. ImmunoGen is trading at a lower price-to-earnings ratio than Verona Pharma, indicating that it is currently the more affordable of the two stocks.

Summary

ImmunoGen beats Verona Pharma on 8 of the 13 factors compared between the two stocks.


Verona Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$33.80+3.0%$1.31 billionN/A0.00Earnings Announcement
Analyst Report
Gap Up
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$31.99+9.3%$1.30 billionN/A0.00Gap Up
Innoviva logo
INVA
Innoviva
1.1$12.78+0.2%$1.29 billion$261.02 million6.52
Endo International logo
ENDP
Endo International
1.5$5.54+0.2%$1.29 billion$2.91 billion-8.15Analyst Revision
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$25.44+0.4%$1.28 billionN/A-2.76
ImmunoGen logo
IMGN
ImmunoGen
1.5$6.69+4.3%$1.28 billion$82.27 million-16.32Earnings Announcement
Analyst Revision
Gap Up
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$30.45+4.8%$1.27 billion$230,000.00-14.16Gap Up
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$29.24+0.3%$1.27 billion$6.20 million-12.82Earnings Announcement
Analyst Upgrade
News Coverage
Gap Down
Zymeworks logo
ZYME
Zymeworks
1.6$28.57+6.8%$1.23 billion$29.54 million-7.58Analyst Report
Gap Up
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.5$35.88+7.0%$1.23 billionN/A-19.93Earnings Announcement
Analyst Revision
Gap Up
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$18.91+1.0%$1.22 billion$73.41 million-4.00Analyst Report
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.81+2.7%$1.17 billion$59.70 million-198.10
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$32.16+3.0%$1.15 billionN/A0.00Earnings Announcement
News Coverage
Gap Down
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$17.98+5.1%$1.14 billion$175.34 million-10.58Gap Down
Omeros logo
OMER
Omeros
1.4$18.52+1.0%$1.14 billion$111.81 million-7.78Earnings Announcement
Analyst Downgrade
Analyst Revision
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$15.08+0.7%$1.14 billion$4.23 million-8.42
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$20.92+1.5%$1.11 billion$4.23 million-15.50
Shattuck Labs logo
STTK
Shattuck Labs
1.5$25.59+2.2%$1.10 billionN/A0.00Earnings Announcement
Insider Selling
Gap Up
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.6$27.31+1.1%$1.09 billion$800.40 million25.76Analyst Report
News Coverage
Keros Therapeutics logo
KROS
Keros Therapeutics
1.5$48.34+4.2%$1.08 billionN/A0.00Analyst Downgrade
Analyst Revision
Gap Down
Zogenix logo
ZGNX
Zogenix
2.0$19.15+0.5%$1.07 billion$3.65 million-2.01Insider Buying
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$33.87+0.4%$1.06 billionN/A-2.42Analyst Upgrade
Insider Selling
Analyst Revision
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$22.69+6.7%$1.06 billionN/A-7.46
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$28.35+3.2%$1.05 billion$57.05 million0.00Earnings Announcement
Analyst Revision
News Coverage
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$18.50+0.5%$1.02 billion$227.19 million51.39Analyst Report
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$51.69+2.7%$1.02 billion$122.47 million-28.40
MannKind logo
MNKD
MannKind
1.4$4.31+6.5%$1.00 billion$63.04 million-20.52Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$14.76+2.8%$990.88 million$42.12 million-10.93Earnings Announcement
Analyst Revision
News Coverage
Humanigen logo
HGEN
Humanigen
1.7$17.68+5.4%$981.33 millionN/A0.00Earnings Announcement
Analyst Report
News Coverage
Gap Up
OLMA
Olema Pharmaceuticals
1.6$24.62+2.2%$966.89 millionN/A0.00Earnings Announcement
Lockup Expiration
Analyst Revision
News Coverage
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$28.23+1.8%$965.56 millionN/A-13.01Earnings Announcement
News Coverage
Radius Health logo
RDUS
Radius Health
1.1$20.58+2.1%$951.95 million$173.32 million-8.43Earnings Announcement
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$14.05+1.6%$943.65 millionN/A-5.93
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$19.87+1.6%$931.74 million$322.36 million141.93Insider Selling
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$20.39+5.8%$919.97 millionN/A-7.52Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Gap Up
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.73+5.5%$917.13 millionN/A-26.60Analyst Revision
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$25.14+3.6%$889.51 millionN/A0.00News Coverage
Gap Up
Epizyme logo
EPZM
Epizyme
1.9$9.12+4.9%$884.13 million$23.80 million-4.09Analyst Report
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.8$18.55+2.4%$873.55 million$1.52 million-9.87Earnings Announcement
Analyst Upgrade
Analyst Revision
Affimed logo
AFMD
Affimed
1.6$9.10+2.6%$870.82 million$23.96 million-15.42News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$8.55+1.2%$870.63 million$120,000.00-3.17Earnings Announcement
Unusual Options Activity
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$21.59+4.2%$870.51 millionN/A-7.44Insider Selling
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.4$17.69+4.0%$869.48 millionN/A0.00News Coverage
Gap Up
Prothena logo
PRTA
Prothena
2.1$22.94+5.7%$865.33 million$810,000.00-8.96Earnings Announcement
Analyst Report
Analyst Revision
Merus logo
MRUS
Merus
1.8$22.07+0.3%$843.70 million$31.13 million-7.19Analyst Revision
News Coverage
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$7.69+4.7%$839.93 million$35.22 million-5.61Analyst Downgrade
Nkarta logo
NKTX
Nkarta
1.8$27.89+14.2%$786.93 millionN/A0.00Earnings Announcement
News Coverage
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.6$22.37+2.8%$766.29 million$296.70 million45.65Insider Selling
Annexon logo
ANNX
Annexon
1.9$20.58+4.2%$754.09 millionN/A0.00
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.4$30.60+0.7%$748.81 millionN/A-9.08Earnings Announcement
Analyst Report
Analyst Revision
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.